SCHEDULE 13G/A: Deep Track Capital Discloses 8.19% Stake in Mind Medicine (MindMed) Inc.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 8.19% in Mind Medicine (MindMed) Inc., totaling 6,500,000 common shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Mind Medicine (MindMed) Inc.
• The reporting persons collectively beneficially own 6,500,000 common shares of Mind Medicine (MindMed) Inc.
• This ownership represents 8.19% of the issuer's common stock.
• The beneficial ownership includes 4,000,000 pre-funded warrants exercisable into common stock, subject to a 9.99% beneficial ownership limitation.
• The percentage of class is calculated based on 79,368,359 common shares, which includes 75,368,359 common stock outstanding as of February 20, 2025 (per the issuer's Form 10-K filed March 6, 2025) and the 4,000,000 pre-funded warrants.
• The reporting persons share both voting and dispositive power over all 6,500,000 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, as required by SEC regulations. It does not contain positive or negative financial performance data, but rather details an institutional investor's significant stake.

Positives

• A significant institutional investor, Deep Track Capital, maintains a substantial stake (8.19%) in Mind Medicine (MindMed) Inc., potentially indicating confidence in the company's long-term prospects.
• The beneficial ownership includes 4,000,000 pre-funded warrants, which could provide future capital to the company upon exercise, although they are subject to a 9.99% beneficial ownership limitation.

Risks

• The beneficial ownership of 4,000,000 pre-funded warrants is subject to a 9.99% beneficial ownership limitation, meaning the holder cannot exercise them if it would result in ownership exceeding this threshold, which could impact the timing or extent of their conversion into common stock.

Future Outlook

The document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic plans, beyond the ongoing nature of the beneficial ownership.

Industry Context

This Schedule 13G filing reflects an institutional investor's significant stake in a biotechnology company, Mind Medicine (MindMed) Inc., which operates in the pharmaceutical and mental health sectors. Such filings are common disclosures for large investors in publicly traded companies across all industries, indicating their position in the market.

Comparison to Industry Standards

• This document is a standard beneficial ownership disclosure (Schedule 13G) filed by an institutional investor, Deep Track Capital, regarding its stake in Mind Medicine (MindMed) Inc. (MMED).
• The 8.19% ownership stake is a substantial position for an institutional investor in a company of this size, aligning with typical large institutional holdings seen in the biotechnology sector.
• For instance, similar significant stakes are often held by specialized biotech funds in companies like Compass Pathways (CMPS) or Atai Life Sciences (ATAI), which also operate in the psychedelic-inspired therapeutics space.
• The inclusion of pre-funded warrants is a common financing mechanism in the biotech industry, allowing for future equity conversion while managing immediate dilution and ownership thresholds.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (8.19%) by Deep Track Capital may be viewed positively by existing shareholders as it indicates institutional confidence and potentially long-term commitment. It also provides transparency regarding major ownership.

Key Dates

Keywords

Mind Medicine (MindMed) Inc., Deep Track Capital, Schedule 13G, beneficial ownership, common shares, pre-funded warrants, MMED, biotechnology, pharmaceuticals, investment, institutional ownership